Cosmederm Technologies

Dura Pharmaceuticals, Inc.

Cosmederm Bioscience, Inc.

Other

Cosmederm, Inc.

David O Thueson

Gary S Hahn

David R Williams

Mark B Mecikalski

Timothy W Quick

Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed.

Methods for inhibiting sensory nerves by topically administering strontium-containing compositions to keratinized skin

Methods for inhibiting sensory responses in the skin such as pain and itch using topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle are disclosed.

Methods for inhibiting sensory responses in the skin such as pain and itch using topical product formulations containing strontium

Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical formulation vehicle, and methods of using these formulations to inhibit skin irritation, are disclosed.

Topical product formulations containing strontium for reducing skin irritation

Compositions and methods are provided for inhibiting skin irritations attributable to chemical irritants or environmental conditions by the application of anti-irritant amounts of aqueous soluble divalent tin cation.

Formulations and methods for reducing skin irritation

A dry powder medicine inhaler has an impeller non-concentrically disposed in a mixing chamber. A motor spins the impeller at high speed. A plunger introduces a dose of powdered medicine into the chamber so that all powder particles are available for intermixing disaggregation and comminution. An aperture receives a first stream of air and passes it towards the mouthpiece for inhalation by the user. A wall has at least one aperture for diverting a portion of a main air stream into the aerosolizing chamber to mix with the particles to form a fine, low-density, low velocity, dry mist of powdered medicine for inhalation by the user.

Dry powder inhaler

Topical formulations comprising an anti-irritant amount of aqueous-soluble strontium (Sr.sup.2+) cation, and method for using the same to inhibit skin irritation are disclosed.

Topical product formulations containing strontium for reducing skin

Topical formulations comprising an anti-irritant amount of aqueous-soluble lithium (Li.sup.+) or potassium (K.sup.+) cation, and methods for using the same to inhibit skin irritation, are disclosed.

Topical formulations comprising an anti-irritant amount of aqueous-soluble strontium (Sr.sup.2+) cation, and methods for using the same to inhibit skin irritation, are disclosed.

An apparatus for aerosolizing a dose of powdered medicine for inhalation, comprising in combination a solid core defining a diskshaped aerosolizing chamber, the chamber defined by spaced-apart, flat front and rear walls terminated by a circumferential wall, the core including a first end piece having formed therein a hollow mouth/nose piece at the front thereof, an impeller non-concentrically disposed in the chamber mounted on a shaft for high-speed powered rotation about a fixed axis, a plunger for instantaneously introducing a full dose of powdered medicine into the aerosolizing chamber so that all particles thereof are available for intermixing disaggregation and comminution, an aperture for receiving a first stream of air interior the core and passing it towards the mouthpiece for inhalation by the user, and, a wall having formed therein at least one aperture for diverting a portion of the first stream into a second stream of air for sweeping through the aerosolizing chamber to mix with the particles to form a fine, low-density, low-velocity, dry mist of powdered medicine for inhalation by the user.

Growing community of inventors

Poway, CA, United States of America

David O Thueson